226 related articles for article (PubMed ID: 7081135)
1. Multiple myeloma: a therapeutic enigma.
Hoogstraten B
Am J Clin Oncol; 1982 Feb; 5(1):13-9. PubMed ID: 7081135
[TBL] [Abstract][Full Text] [Related]
2. [New aspects in the clinical course determination and therapy in multiple myeloma].
Ludwig H; Pietschmann H
Acta Med Austriaca; 1979; 6(5):255-60. PubMed ID: 555224
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
[TBL] [Abstract][Full Text] [Related]
4. Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
[No Abstract] [Full Text] [Related]
6. Current concepts in cancer. Multiple myeloma.
McIntyre OR
N Engl J Med; 1979 Jul; 301(4):193-6. PubMed ID: 377077
[No Abstract] [Full Text] [Related]
7. Multiple myeloma: results with the M-2 protocol in a community hospital.
Miller S; Perrotta AL
J Am Osteopath Assoc; 1979 Aug; 78(12):857-64. PubMed ID: 489428
[No Abstract] [Full Text] [Related]
8. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
[TBL] [Abstract][Full Text] [Related]
9. [Primary treatment results in myeloma disease using a cytostatic preparation].
Iavorkovskiĭ LI; Soloveĭ DIa; Udris OIu; Riauzova LIu; Bliumental' RIa
Probl Gematol Pereliv Krovi; 1981 Aug; 26(8):36-40. PubMed ID: 7301789
[No Abstract] [Full Text] [Related]
10. [Clinical study on chemotherapy for multiple myeloma. Part III: The disappearance of M-protein in multiple myeloma].
Adachi T; Hasegawa M; Asano K; Sezaki T; Ishii H; Takahashi I; Kimura I
Rinsho Ketsueki; 1983 Apr; 24(4):440-7. PubMed ID: 6887544
[No Abstract] [Full Text] [Related]
11. [Therapy of paraproteinemic hemoblastoses].
Fereberger W
Acta Med Austriaca; 1982; 9(4):151-7. PubMed ID: 6814158
[TBL] [Abstract][Full Text] [Related]
12. [Determination of the tumor cell mass and its significance as a parameter for prognosis and therapy in patients with multiple myeloma].
Ludwig H; Schneider K; Pietschmann H
Acta Med Austriaca; 1978; 5(4-5):164-6. PubMed ID: 756132
[TBL] [Abstract][Full Text] [Related]
13. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
14. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study on chemotherapy for multiple myeloma. Part II: Prognostic factors of treatment with prednisolone and sequential melphalan and ifosfamide: MIP therapy].
Sezaki T; Ishii H; Adachi T; Takahashi I; Ohnoshi T; Kimura I
Rinsho Ketsueki; 1983 Apr; 24(4):433-9. PubMed ID: 6887543
[No Abstract] [Full Text] [Related]
16. [Chemotherapy of multiple myeloma. Review of the recent trials].
Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
[No Abstract] [Full Text] [Related]
17. [Clinical study on the chemotherapy of multiple myeloma. 1. Therapeutic effect of sequential combination therapy using melphalan, ifosfamide, and prednisolone].
Sezaki T; Ishii H; Osada T; Adachi T; Takahashi I; Ohnoshi T; Kimura I
Rinsho Ketsueki; 1982 Jun; 23(6):847-53. PubMed ID: 7176091
[No Abstract] [Full Text] [Related]
18. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
19. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
[TBL] [Abstract][Full Text] [Related]
20. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
